Rozlytrek

Generic name: entrectinib

Used for: ROS1-positive non-small cell lung cancer · Solid tumors with an NTRK gene fusion · 1 more

How do you pay?

How to pay the least

Ask for the cash price

Rozlytrek

We didn’t find one.

  1. Ask your pharmacy for Rozlytrek’s cash price, and one or two other pharmacies too.

Free from the maker, if you qualify Genentech Patient Foundation. Do not have insurance coverage for their Genentech medicine and their household makes less than $150,000 per year Or call (888) 941-3331.

See if you qualify 

Compare every option

Question
Brand nameRozlytrek
Authorized genericentrectinib
Regular genericentrectinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Rozlytrek?
The original
–
–

Brand nameThe maker’s card

Genentech Oncology Co-pay Assistance Program

Savings card from Genentech

Rozlytrek’s maker has a savings program. Its page doesn’t list a dollar amount.

Sign up on genentech-pro.com 

Or call 1-855-692-6729.

From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.

Authorized genericNot sold

There isn’t one. An authorized generic is Rozlytrek itself, from the same company, sold without the brand name, and usually for less. For now Rozlytrek is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ROZLYTREK is a kinase inhibitor indicated for the treatment of:

  • Adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
  • Adult and pediatric patients older than 1 month of age with solid tumors that:
    • have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation,
    • are metastatic or where surgical resection is likely to result in severe morbidity, and
    • have progressed following treatment or have no satisfactory alternative therapy.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Source: the FDA label for Rozlytrek (Genentech, Inc.), October 8, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/rozlytrek/